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The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine
kinases that are activated by the binding of triple-helical collagen. Excessive signaling by DDR1 and DDR2
has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer.
We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib
and ponatinib, as well as the selective type II inhibitor DDR1-IN-1. Ponatinib is identified as the more potent
molecule, which inhibits DDR1 and DDR2 with an IC50 of 9 nM. Co-crystal structures of human DDR1 reveal a
DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge
between the activation loop and αD helix. Differences to Abelson kinase (ABL) are observed in the DDR1
P-loop, where a β-hairpin replaces the cage-like structure of ABL. P-loop residues in DDR1 that confer drug
resistance in ABL are therefore accommodated outside the ATP pocket. Whereas imatinib and ponatinib bind
potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly
satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity. Such inhibitors may have
applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
The discoidin domain receptors (DDRs), DDR1
and DDR2, are unique among the receptor tyrosine
kinases (RTKs) in being activated by interaction with
the extracellular matrix [1,2]. Binding to triple-helical
collagen is mediated by the receptor extracellular
domains that include an N-terminal discoidin (DS)
domain, a DS-like domain and a short juxtamem-
brane (JM) region [3–5]. A single transmembrane
helix links to the cytoplasmic domain, where a larger
JM region precedes the catalytic C-terminal kinase
domain. Both DDRs form constitutive dimers making
them unusual among RTKs, which typically dimerize
only upon activation [6–8]. DDRs regulate extracel-Authors. Published by Elsevier Ltd. T
org/licenses/by/3.0/).lular matrix remodeling, as well as cell adhesion,
proliferation and migration [9]. DDR1 is expressed
mainly in epithelial cells where it plays an important
role in mammary gland development [10], whereas
mesenchymal expression of DDR2 promotes bone
growth, as suggested by dwarfism in DDR2 knock-
out mice [11].
DDRkinases are linked to the progression of various
human diseases, including fibrotic disorders, athero-
sclerosis and cancer [9,12,13]. Significantly, they are
identified as indicators of poor prognosis in ovarian,
breast and lung cancer [14–16]. DDR1 overexpres-
sion is associated with increased cell survival and
invasion in hepatocellular carcinomas, pituitary ade-
noma and prostate cancer [17–19], whereas DDR2 ishis is an open access article under the CC BY license
J. Mol. Biol. (2014) 426, 2457–2470
2458 Inhibition of the Collagen Receptor DDR1mutated in squamous cell lung cancers [20] and
contributes to breast cancer metastasis [21]. The
promise of DDR kinases as a therapeutic target has
been demonstrated by DDR1 knockdown that has
been shown to reduce metastatic activity in lung
cancer models [22], slow the development of athero-Fig. 1. Overview of the DDR1 structure. (a) Domain organ
domain in complex with the inhibitor ponatinib. (c) Chemical str
“linker” and “tail” regions. (d) Sequence alignment of the kinas
elements are displayed for the DDR1 kinase. Residues labeled
and ponatinib. Residues labeled with a double dagger (‡) formsclerosis [13] and impede the development of fibrotic
disorders [23–25].
Imatinib (STI-571) is a first-line tyrosine kinase
inhibitor (TKI) targeted at breakpoint cluster region-
Abelson kinase (ABL) for the treatment of chronic
myeloid leukemia (CML) [26]. As a type II inhibitor,ization of DDR1. (b) Crystal structure of the DDR1 kinase
uctures of imatinib and ponatinib, highlighting their “head”,
e domains of DDR1, DDR2 and ABL. Secondary structure
with an asterisk (*) form hydrogen bonds with both imatinib
hydrogen bonds with imatinib only.
Table 1. Data collection and refinement statistics.
DDR1–ponatinib
(3ZOS)
DDR1–imatinib
(4BKJ)
Data collection
X-ray source Diamond Light
Source I04-1
Diamond Light
Source I03
Wavelength (Å) 0.92 0.9795
Resolution range (Å)a 45.41–1.92
(1.988–1.919)
45.14–1.7
(1.76–1.699)
Space group P1211 P212121
Unit cell (Å)
a 69 60
b 61.7 60
c 80.2 180.6
Unit cell (°)
α 90 90
β 104.4 90
γ 90 90
2459Inhibition of the Collagen Receptor DDR1imatinib achieves significant selectivity by binding to an
inactive DFG-out conformation (DFG, Asp-Phe-Gly) of
the kinase domain [27]. A chemical proteomics study
recently identified DDR1 as a secondary target of
imatinib, leading to the suggestion that DDR1 inhibition
may also contribute to the effectiveness of the
treatment [28], particularly as activation of DDR1 is
known to block p53-mediated apoptosis [29]. Further
characterization of this interaction revealed imatinib to
be a potent inhibitor of DDR1, as were the second-
generation TKIs nilotinib and dasatinib [30]. Moreover,
dasatinib may have potential to treat squamous cell
lung cancer in patients harboring oncogenic mutations
in DDR2 [20]. Imatinib also rescues mouse models of
fibrosis [31,32] similarly to DDR1 deficiency [25],
although a connection between these effects has yet
to be proven. Ponatinib is a third-generation TKI
developed for the treatment of CML patients with
resistance to imatinib [33,34]. It was selected primarily
to circumvent the steric hindrance introduced by the
ABL T315I “gatekeeper” mutation and has proven to
be a more potent but considerably less selective
inhibitor than imatinib [30]. Finally, the inhibitor
DDR1-IN-1 was designed to a similar pharmacophore
model as these multi-targeted type II kinase inhibitors
but has been recently reported as a highly selective
pharmacological probe for DDR1-dependent signal
transduction [35]. Such inhibitors will be highly
valuable to investigate further the complex roles of
DDR1 in both normal and pathobiology. In addition,
more selective compounds are likely to offer improved
safety profiles for potential clinical indications outside
oncology.
While crystal structures of DDR1 and DDR2 have
revealed themolecular basis for extracellular collagen
interaction [5,36], a structural description of the kinase
domain fold is lacking. Here, we present the crystal
structures of the kinase domain of human DDR1 in
complexes with the inhibitors imatinib and ponatinib,
as well as structural comparisons to the selective
inhibitor DDR1-IN-1. The structures reveal differences
to ABL in both the shape and the sequence of the ATP
pocket that can be exploited for the design of DDR1-
specific inhibitors.Unique reflectionsa 49,502 (3453) 72,847 (4093)
Multiplicitya 6.1 (6.1) 6.5 (6.5)
Completeness (%)a 99 (98.7) 99.9 (99.7)
I/σ(I)a 9.1 (2.7) 13.5 (2.9)
Rmerge
a 0.137 (0.785) 0.08 (0.632)
Refinement
Rwork 0.206 0.157
Rfree 0.234 0.176
Number of atoms 5224 5175
RMSD bonds (Å) 0.012 0.007
RMSD angles (°) 1.49 1.23
Average B-factor (Å2) 23.8 24.6
Average B-factor
macromolecules (Å2)
23.7 24.3
Average B-factor ligands (Å2) 19.8 21.8
Average B-factor solvent (Å2) 26.4 30.6
a Values in parentheses refer to the highest-resolution shell.Results
Structure determination
The kinase domain of human DDR1 (residues 601–
913; Fig. 1a) was expressed in Sf9 insect cells and
purified using nickel affinity and size-exclusion chro-
matography. Crystal structures (Fig. 1b) were deter-
mined in separate complexeswith the kinase inhibitors
imatinib and ponatinib, respectively (Fig. 1c). The
ponatinib co-structure was solved by molecular re-
placement using tropomyosin-related kinase B (TrkB)(PDB ID: 4AT5) [37] as a search model and refined at
1.9 Å resolution (see Table 1 for data collection and
refinement statistics). The complete main chain was
traceable, except for residues 721–731, which were
not visible in the electron density map. This site,
corresponding to a small kinase insert domain (KID),
was one of several sequence insertions identified
relative to the comparable kinase domain structure of
ABL (Fig. 1d). The DDR1–imatinib complex structure
was solved subsequently using data collected from
crystals improved by microseeding procedures (see
Materials and Methods). The structure was solved by
molecular replacement and refined to 1.7 Å resolution.
Disordered regions in the imatinib co-structure were
identified in both the KID region and a portion of the
activation segment spanning residues 799–803. The
two inhibitor complexes exhibited distinct crystal
packing leading to small differences in their respective
structures (Fig. 2). DDR1 was monomeric in the
imatinib complex, consistent with its size-exclusion
profile, whereas the ponatinib complex formed a crys-
tallographic dimer with an additional ponatinib mole-
cule bound at the dimer interface (Fig. 2).
Overall, DDR1 displays the classical bilobal archi-
tecture of a tyrosine kinase (Fig. 1b). An N-terminal
extension folds across the top of the smaller
Fig. 2. Crystal packing in the DDR1–ponatinib complex. (a) The asymmetric unit of the DDR1–imatinib structure
contains two protein monomers. Asterisks mark the disordered regions of the activation segments corresponding to
strands β8 and β9. (b) The asymmetric unit of the DDR1–ponatinib structure contains a crystallographic dimer held by the
self-association of the β8-β9 hairpin (colored blue and orange in chains A and B, respectively). (c) The dimer interface is
stabilized by the binding of an additional ponatinib molecule. The linker and tail regions of the interfacial ponatinib molecule
contact hydrophobic residues on the lower face, where they also hydrogen bond to the carbonyl of Ile815 (αEF helix) in
each protein chain. The opposite face of the β-sheet is stabilized by contacts with the αC helix and phosphate-binding loop
(P-loop), including a salt bridge between Arg798 (β8) and Asp668 (αC) (data not shown). (d) Perhaps as a result of these
different packing interactions, DDR1 monomers from the imatinib and ponatinib co-structures show a subtle shift in the
relative positions of the N-terminal kinase lobes.
2460 Inhibition of the Collagen Receptor DDR1N-terminal lobe, which comprises β1–β5 strands and
the αC helix. In the α-helical C-terminal lobe, the
activation segment includes an additional β-hairpin
motif formed by strands β8 and β9 (Fig. 1b and d). As
observed for ABL, both type II inhibitors induce an
inactive conformation of DDR1 characterized by a
“DFG-Asp out, αC-Glu in” configuration. In this
conformation, the catalytically relevant salt bridge is
observed between DDR1 residues Glu672 (αC) and
Lys655 (β3), but the remaining catalytic site is
disrupted by an inverted conformation of the DFG
motif in the activation loop (A-loop).The DDR family fold
Comparable inhibitor-bound structures of DDR1
and ABL show a global root-mean-square deviation
(RMSD) of 3.6 Å over 248 Cα atoms (Fig. 3a), with
identical values for the respective imatinib and
ponatinib complexes. DDR1 contains a notable
insertion between the β2 and β3 strands, where
amino acids 629–650 form a structured loop of 22
residues that is double the length of the same region in
the closely related kinases insulin-like growth factor 1
receptor (IGF1R) [40], MUSK (muscle, skeletal
Fig. 3. Structural comparison of DDR1 and ABL. (a) Superposition of the structures of DDR1 and ABL–imatinib (PDB
ID: 2HYY) [38] reveals a number of structural changes that are highlighted by boxed regions. (b) Sequence alignment of
the activation segment of selected kinases. The three potential sites of phosphorylation in DDR1 are highlighted by
asterisks. The same region is highlighted on the DDR1 structure (right) showing the same tyrosine side chains in DDR1
(red with residue numbers displayed), IGF1R (PDB ID: 1P4O; green) [39] and ABL (blue) [38].
2461Inhibition of the Collagen Receptor DDR1receptor tyrosine protein kinase) [41] and TrkB [37].
These residues fold across the top of the N-lobe
forming hydrophobic interactions with the N-terminal
extension and β5 strand. The N-lobes also differ in the
P-loop, which in DDR1 remains bound to β3 as a
β-hairpin in contrast to the cage-like structure of ABL
that dissociates to envelope the bound imatinib
(Fig. 3a). Two additional sequence insertions are
identified in the C-lobe. Firstly, DDR1 contains a small
KID located between helices αD and αE, although 12
of these 23 residues are disordered (Fig. 3a). Sec-
ondly, an insert of 7 residues follows the DDR1 αG
helix leading to a difference of 6.8 Å in the positions of
the DDR1 and ABL chains at this site (Fig. 3a).
Similar insertions are predicted in DDR2, although
the KID region appears 9 residues shorter in this
protein (Fig. 1d). The two DDR family membersshare 68% sequence identity within their kinase
domains, with the highest conservation as expected
in the catalytic core and activation segments. In
particular, the P-loop and ATP pocket residues of
DDR1 and DDR2 are strictly conserved suggesting
that their inhibitor binding preferences will be similar.
Both kinases contain three potential sites of tyrosine
phosphorylation in their A-loops corresponding to
DDR1 Tyr792, Tyr796 and Tyr797. Their packing
closely matches that of the conserved residues in
the inactive structures of IGF1R [40], MUSK [41] and
TrkB [37] (Fig. 3b). In particular, DDR1 Tyr796
adopts a conserved position as a pseudosubstrate,
as observed also for the single tyrosine in ABL [38]
(Fig. 3b). Mass spectrometry confirmed that the
DDR1 kinase domain was expressed and purified in
a non-phosphorylated state.
2462 Inhibition of the Collagen Receptor DDR1Interactions of the P-loop
Perhaps the most important sequence changes in
the DDR family occur in the P-loop, where ABL
mutations conferring imatinib resistance (Gly250Glu
and Tyr253Phe) match the native DDR sequence
(DDR1 Glu618 and Phe621, respectively). In ABL,
Tyr253 forms a hydrogen bond with Asn322 to
stabilize the cage-like structure of the P-loop, while
Gly250 likely contributes to the flexibility required for
this fold (Fig. 4). This P-loop conformation also
affords additional van der Waals interactions with the
inhibitor. As a result of its phenylalanine substitution,
the same hydrogen bond cannot be formed in DDR1
and its P-loop retains the common β-hairpin confor-
mation. Interestingly, the missing P-loop interactions
are replaced by the A-loop, which inserts DDR1
Arg789 into the ATP pocket to hydrogen bond with
the Asn322-equivalent residue Asp708 (Fig. 4). This
conformation is further stabilized by main-chain
hydrogen bonding between the P-loop and A-loop
(data not shown). Thus, the alternative structure of
DDR1 removes Glu618 and Phe621 from the binding
site into solvent while maintaining suitable ATP
pocket interactions for inhibitor binding.
Binding of imatinib and ponatinib
As anticipated, the binding of both type II inhibitors is
facilitated by an inverted conformation of the DFG
motif that exposes an additional binding pocket below
the αC for the inhibitor tail, while the head groups bind
to the hinge. In total, imatinib forms six hydrogenFig. 4. DivergentP-loop structures inDDR1andABL lead
to changes in ATP pocket shape. Superposition of the
DDR1–imatinib (white) and ABL–imatinib (PDB ID: 2HYY;
magenta) [38] complexes. DDR1 Glu618 and Phe621 are
equivalent to the drug resistance mutations Gly250Glu and
Tyr253Phe in ABL. Different conformations are also ob-
served for the A-loop where DDR1 Arg789 corresponds to
ABL Arg386.bonds in theATPpocket of DDR1 (Fig. 5a). Two target
the hinge region, including one between the pyridine
head group and the backbone amide of Met704 and
one between the aminopyrimidine and the gatekeeper
residue Thr701. Twomore are made by the linker: the
amide binds to Glu672 in the αC, while the carbonyl
contacts the backbone amide of Asp784 in the DFG
motif. Finally, the methylpiperazine group occupies a
hydrophobic pocket between the αC and HRD
(His-Arg-Asp) motif and hydrogen bonds with the
backbone carbonyls of Val763 and His764. The DFG
motif further stabilizes the binding with a π–π stacking
interaction between Phe785 and the aminopyrimidine
group (Fig. 5a). The strongbinding of DDR1 to imatinib
was revealed by isothermal titration calorimetry (ITC),
which indicated a dissociation constant (KD) of 1.9 nM
(Fig. 5b). To confirm the ability of imatinib to inhibit
DDR1kinaseactivity in cells, wemeasured its ability to
block collagen-induced DDR1 autophosphorylation in
U2OS cells. Again, imatinib demonstrated significant
potency against DDR1 yielding an EC50 of 21 nM.
By design, ponatinib binds at the same site with the
loss of one hydrogen bond owing to the ethynyl linker,
which removes any polar interaction with the gate-
keeper residue Thr701 (Fig. 6a). Hinge interactions
are made instead by an imidazo[1,2b]pyridazine head
group, which establishes the hydrogen bond with
Met704. In addition to the remaining four hydrogen
bonds, there are extensive hydrophobic interactions
across theDDR1pocket, although theπ–π interaction
with Phe785 is broken (Fig. 6a). The added trifluor-
omethyl group occupies the pocket vacated by the
inverted DFG motif and forms favorable hydrophobic
contacts with Leu679, Ile684, Ile685, Leu757 and
Ile782 (Fig. 6a). ITC measurements suggested that
the ponatinib interaction was slightly stronger than
imatinib, with a calculated KD of 1.3 nM (Fig. 6b).
Similar potency was observed in U2OS cells, where
ponatinib inhibited collagen-inducedDDR1 autophos-
phorylation with an EC50 of 2.5 nM (Fig. 6d).
The tight binding of both inhibitors can be under-
stood from the similar inhibitor bindingmodesofDDR1
and ABL, which share a conserved threonine gate-
keeper in their hinge regions (Supplementary Fig. S1).
Importantly for inhibitor design, the ATP pocket of
DDR1 also shows a number of sequence changes.
Several substitutions cluster around the inhibitor tail
region, where DDR1 Ile675 (αC), Leu679 (αC), Ile684
(αC-β4 loop) and Ile685 (αC-β4 loop) replace ABL
Val289, Ile293, Leu298 and Val299, respectively.
Other changes include Tyr703 (ABL Phe317) in the
hinge and Met699 (ABL Ile313, β5), which packs
above the methylphenyl linker.
Differences to the binding mode of DDR1-IN-1
Recently we reported the discovery of a type II
kinase inhibitor, DDR1-IN-1, with striking selectivity
for DDR1 (Fig. 7a; PDB ID: 4CKR) [35]. This inhibitor
Fig. 5. DDR1 binding and inhibition by imatinib. (a) Interactions of imatinib in the ATP pocket of DDR1. Colors
correspond to the structural features indicated in Fig. 1. Hydrogen bond interactions are shown as dotted lines. (b) ITC
measurements of the binding show a KD value of 1.9 nM. (c) Imatinib efficacy on blocking collagen-induced DDR1 Y513
autophosphorylation in U2OS cells.
2463Inhibition of the Collagen Receptor DDR1binds the DFG-out conformation of DDR1 in a similar
fashion to imatinib. The carbonyl of its indolin-2-one
head group forms a hydrogen bond with Met704 in
the hinge, similar to the interactions of imatinib and
ponatinib (Fig. 7b). However, the ether bridge of
DDR1-IN-1 eliminates the hydrogen bond to the
gatekeeper residue Thr701. Similar binding interac-
tions are also observed across the tail region of
DDR1-IN-1 (Fig. 7c), where the trifluoromethyl
groups of both DDR1-IN-1 and ponatinib occupy
the same hydrophobic pocket created by the flip of
the DFG motif.
To rationalize why DDR1-IN-1 is selective for DDR1
(IC50 = 105 nM) relative to ABL (IC50 = 1.8 μM), we
modeled the DDR1 co-crystal structure (PDB ID:
4CKR) onto the ABL–imatinib complex (PDB ID:
2HYY). While the overall binding modes of the two
inhibitors are predicted to be similar, one notable
difference is that the ether bridge of DDR1-IN-1adopts a different dihedral angle relative to the aniline
NH of imatinib (Fig. 7b). As a result, the indolin-2-one
head group of DDR1-IN-1 is orientated away from the
ABL P-loop disrupting critical hydrophobic interac-
tions with ABL Tyr253 and the hydrogen bond to the
gatekeeper threonine (Fig. 7d). In addition, the
hydrogen bond between Met318 in the ABL hinge
and the lactam carbonyl of DDR-IN-1 is predicted to
be approximately 3.0 Å, which is longer than the 2.6 Å
hydrogen bond observed in the DDR1 complex.
These predictions require examination of an experi-
mental ABL structure with DDR1-IN-1.
Finally, to investigate the chemical features required
in the linker and tail moieties of DDR1-IN-1, we
prepared seven analogs and tested their ability
alongside imatinib and ponatinib to inhibit DDR1 and
DDR2 kinase activity (Table 2 and Supplementary
Fig. S2) [42]. Ponatinib potently inhibited both DDR
kinases with an IC50 of 9 nM. Inhibition by imatinib
Fig. 6. DDR1 binding and inhibition by ponatinib. (a) Interactions of ponatinib in the ATP pocket of DDR1. Colors
correspond to the structural features indicated in Fig. 1. Hydrogen bond interactions are shown as dotted lines. (b) ITC
measurements of the binding show a KD value of 1.3 nM. (c) Ponatinib efficacy on blocking collagen-induced DDR1 Y513
autophosphorylation in U2OS cells.
2464 Inhibition of the Collagen Receptor DDR1was slightly weaker with DDR1 and DDR2 exhibiting
IC50 values of 41 and 71 nM, respectively. DDR1-IN-1
also retained significant activity against DDR1 (IC50 =
105 nM) despite the loss of the hydrogen bond to
Thr701 and a reduction in theπ–π stacking interaction
that is observed between Phe785 and imatinib. We
found that potency against the DDR kinases was
decreased slightly when the amide between the linker
and tail moieties was replaced with urea (1). Replace-
ment of the methylpiperazine with an ether-linked
methylpiperidine (2) resulted in a compound that
retained the potency of DDR1-IN-1. Switching to a
3,5-substitution pattern (3,4) resulted in a slight
decrease in potency relative to the 3,4-substitution
pattern of DDR1-IN-1. Deletion of the methylpiper-
azine was tolerated when a hydrophobic 3-position
substituent was maintained (5). Removal of the
trifluoromethyl group resulted in analogs (6,7) that
were inactive suggesting that a hydrophobic inter-
action near the DFG motif is likely essential for
DDR1-IN-1.Discussion
The structures presented here were solved at high
resolution and show in detail how DDR1 achieves
high affinity for imatinib and ponatinib, respectively.
Both type II inhibitors bind in their more potent
extended conformations to the inactive DFG-out
conformation of the kinase domain. Differences to
ABL are observed primarily in the P-loop, where
DDR1 adopts the active conformation common to
the KIT–imatinib complex (KIT, mast/stem cell
growth factor receptor) [43]. As a result, residues in
the DDR1 P-loop that confer drug resistance when
introduced in ABL are solvent exposed and tolerat-
ed. DDR1 also assembles a cage-like structure
around the inhibitor pocket by tethering the activation
segment to the αD helix. This alternative loop
arrangement stabilizes the DFG-out conformation
of DDR1 and establishes a distinct packing from
other structures. This conformation is exploited by
the first DDR1-selective type II inhibitors that carry
Fig. 7. Structural basis for DDR1-IN-1 selectivity. (a) Chemical structure of DDR1-IN-1. (b) Superposition of the ABL–
imatinib complex (red; PDB ID: 2HYY) and the DDR1-IN-1 complex with DDR1 (green; PDB ID: 4CKR) [35]. A green
surface representation defines the shape and extent of the ATP pocket in DDR1. The alternative hinge interactions of the
two inhibitors are highlighted. (c) Superposition as in (b) highlighting the interactions of the inhibitor “tail” regions. (d) The
ether bridge of DDR1-IN-1 orientates the indolin-2-one “head” group away from the ABL P-loop disrupting critical
hydrophobic interactions with Tyr253.
2465Inhibition of the Collagen Receptor DDR1variant head and linker moieties that restrict interac-
tion with the gatekeeper residue [35,44]. Interesting-
ly, the ether bridge of DDR1-IN-1 is also found in the
MET (hepatocyte growth factor receptor) inhibitor
LY2801653, which has entered clinical trials for
advanced cancer and inhibits DDR1 with IC50 and
EC50 values of less than 1 nM [45].
Imatinib-mediated inhibition of breakpoint cluster
region-ABL has shown remarkable safety and efficacy
against CML [26]. Perhaps more significantly, the
recognition of imatinib activity against other kinases,
notably KIT and PDGFR (platelet-derived growth
factor receptor), has led to its effective use in other
oncology indications [46,47] and ongoing clinical trials
in fibrosis [48]. Collagen-induced activation of the
RTKsDDR1 and DDR2 is similarly observed in fibrotic
diseases and neoplastic tissue suggesting that DDR
inhibition may be a beneficial off-target effect. Further-more, ponatinib and dasatinib show potent activity
againstmutant DDR2 inmodels of squamous cell lung
cancer [20] and indeed dasatinib has entered clinical
trials for this indication [49]. DDR kinases share a
conserved threonine gatekeeper residue with ABL
and are therefore likely to remain susceptible to drug
resistance mutations at this site. The aminopyrimidine
head group of imatinib is hydrogen bonded to the
gatekeeper Thr701 in DDR1 analogous to its interac-
tion with the gatekeeper Thr315 in ABL [27]. In CML,
mutation of the gatekeeper Thr315 to Ile confers drug
resistance [50], suggesting that an analogous muta-
tion in DDR1 and DDR2 would also confer resistance
to imatinib.
Ponatinib overcomes drug resistance arising from
the gatekeeper position but acquires reduced selec-
tivity and increased off-target effects. Interesting in this
respect is the ponatinib molecule that stabilizes the
Table 2. Structure–activity relationship of DDR1-IN-1.
Compounds R Enzymatic IC50 values (nM)
DDR1 DDR2
Ponatinib 9.4 9.0
Imatinib 41 71.6
DDR-IN-1 105 413
1 262 785
2 115 338
3 182 546
4 150 385
5 174 1020
6 N10,000 N10,000
7 8940 N10,000
2466 Inhibition of the Collagen Receptor DDR1crystallographic dimer in the kinase–inhibitor complex.
While we have not investigated this effect in solution, it
may be of relevance for the full-length DDR1 and
DDR2 receptors, which form constitutive homodimers
at the cell surface. It may therefore be of interest in the
future to screen this allosteric site against a library of
ponatinib derivatives to identify compounds that
stabilize this inactive kinase conformation.
In summary, we report the crystal structures of the
human DDR1 kinase domain in complex with two
clinically relevant kinase inhibitors and identify struc-
tural features that determine the binding of DDR-se-
lective inhibitors. The high affinity of these interactionssupports the potential use of these molecules to
control excessive DDR signaling in diseases such as
inflammation, fibrosis and lung cancer.Materials and Methods
Chemicals
Unless otherwise noted, reagents and solvents were
obtained from commercial suppliers and were used without
further purification. For crystallization, imatinib was pur-
chased from LC Laboratories whereas ponatinib was
2467Inhibition of the Collagen Receptor DDR1purchased from Selleck Chemicals. DDR1-IN-1 was pre-
pared as described previously [35]. Synthesis of DDR1-IN-1
derivatives is described in Supplementary Material.
Cloning
The DNA sequence corresponding to the kinase domain
of human DDR1 (UniProt Q08345; residues 601–913) was
cloned into the transfer vector pFB-LIC-Bse by ligation-
independent cloning. The vector encodes an N-terminal
hexahistidine tag and a tobacco etch virus protease A
(TEV) cleavage site. Bacmid DNA was prepared from
Escherichia coli strain DH10Bac and used to generate
baculovirus in Sf9 insect cells.
Protein expression and purification
Baculovirus was used to infect Sf9 cells grown in
suspension to a density of 2 × 106 cells/mL in Insect-
Xpress media (Lonza). Cells were incubated at 27 °C and
harvested 72 h post-infection. Harvested cells were
resuspended in binding buffer [50 mM Hepes (pH 7.5),
500 mM NaCl, 5% glycerol and 5 mM imidazole] supple-
mented with protease inhibitor cocktail set III (Calbiochem)
at 1:1000 dilution and 1 mM tris(2-carboxyethyl)phosphine
(TCEP). Cells were disrupted by high-pressure homoge-
nization. Polyethylenimine was added to a final concen-
tration of 0.5% to precipitate DNA and the cell lysate was
clarified by centrifugation at 21,000 RPM for 1 h at 4 °C.
DDR1 protein was purified using nickel-Sepharose resin
(GE Healthcare) and eluted stepwise with imidazole.
Following tag cleavage, we purified the protein further by
size-exclusion chromatography using a HiLoad Superdex
S75 26/60 column (GE Healthcare) buffered in 10 mM
Hepes (pH 7.5), 250 mM NaCl, 5% glycerol and 1 mM
TCEP. The eluted DDR1 protein was supplemented with
5 mM L-arginine, 5 mM L-glutamate and 2 mM dithiothre-
itol before concentrating for crystallization. The intact mass
of the unphosphorylated protein was confirmed by
electrospray ionization/time-of-flight mass spectrometry
(Agilent Technologies).
Crystallization and structure determination
Inhibitors were added to the concentrated protein in
1.5-fold molar excess and the protein solution was
centrifuged at 14,000 RPM prior to crystallization. The
DDR1–ponatinib complex was crystallized at 4 °C in
150 nL sitting drops mixing 100 nL protein solution at
11 mg/mL with 50 nL of a reservoir solution containing
0.1 M 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)pro-
pane-1,3-diol (pH 5.5) and 25% (w/v) polyethylene glycol
3350. On mounting crystals were cryo-protected with an
additional 25% ethylene glycol. Diffraction data were
collected at 100 K on Diamond Light Source beamline
I04-1. Crystals belonged to the monoclinic space group
P1211. Two protein molecules were present in the
asymmetric unit.
The DDR1–imatinib complex was crystallized at 20 °C
in 150 nL sitting drops mixing 50 nL protein solution at
8 mg/mL with 100 nL of a reservoir solution containing
0.1 M 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)pro-
pane-1,3-diol (pH 6.3) and 34% (w/v) polyethylene glycol3350. After 4 h, 20 nL of DDR1–ponatinib seed crystals
was added to initiate crystal growth. On mounting crystals
were cryo-protected with an additional 25% ethylene
glycol. Diffraction data were collected at 100 K on
Diamond Light Source beamline I03. Crystals belonged
to the orthorhombic space group P212121. Two protein
molecules were present in the asymmetric unit.
Data were indexed and integrated using XDS [51] and
scaled using AIMLESS [52,53] in the CCP4 suite of
programs [54]. Phases were found using molecular
replacement in Phaser [55]. PHENIX.SCULPTOR was
used to optimize PDB ID: 4AT5 (TrkB) [37] for use as a
search model. The structures were built using PHENIX.
AUTOBUILD [56] and then refined and modified using
alternate rounds of REFMAC5 [57] and Coot [58,59]. TLS
groups were determined using the TLSMD server [60]. The
refined structures were validated with MolProbity [61] and
the atomic coordinate files were deposited in the Protein
Data Bank with Autodep [62]. Structure figures were
prepared with PyMOL [63].
Isothermal titration calorimetry
Experiments were performed at 15 °C using a Microcal
VP-ITCmicrocalorimeter. Protein and ligands were buffered
in 50 mM Hepes (pH 7.5), 250 mM NaCl, 1 mM TCEP and
2%DMSO.We titrated 100 μMDDR1 into inhibitor solutions
at 10 μM concentration. Data were analyzed using a single
binding site model implemented in the Origin software
package provided with the instrument.
IC50 determination
IC50 values were determined by Invitrogen using a
LanthaScreen kinase activity assay.
EC50 determination
U2OS cells containing tetracycline-inducible human
HA-FLAG-DDR1 expression were used for the EC50 test.
DDR1 was induced by 2 μg/mL doxycycline for 48 h prior
to DDR1 activation by rat tail collagen I. The cells were
pre-treated by media containing each concentration of the
compound for 1 h and treated by changing the media to the
EC50 test media containing 10 μg/mL collagen and each
concentration of the compound for 2 h. Cells were washed
with cold phosphate-buffered saline three times and lysed
with lysis buffer [20 mM Tris (pH 7.5), 5 mM ethylenedi-
aminetetraacetic acid, 1% Triton X-100, protease inhibitor
cocktail and phosphatase inhibitor cocktail]. The phosphor-
ylation of DDR1 and total DDR1 expression were quantified
by using the ImageJ program following Western blot using
anti-human DDR1b (Y513) and anti-HA, respectively.
β-Actin was blotted as loading control. The EC50 concen-
tration was calculated by nonlinear regression analysis
using GraphPad Prism software.
Protein Data Bank accession numbers
Atomic coordinates and structure factors have been
deposited in the Protein Data Bank under accession
numbers 3ZOS and 4BKJ.
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